Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of VAQTA Given Concomitantly with ProQuad and Prevnar in Children
NCT00312858Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2006
- Primary completion
- Mar 2008
- Modality
- Whole Inactivated Vaccines
01
Overview
Phase 4, randomised, open-label trial of inactivated hepatitis A virus vaccine in hepatitis A (HAV) (2 arms), sponsored by Merck & Co. Primary endpoints: Antibody Response to Hepatitis A - Participants With a Serological Response, Antibody Response to Varicella - Participants With a Serological Response and 5 more. Started Apr 2006; status: completed.
02
Drugs
inactivated hepatitis A virus vaccine
03
Conditions
hepatitis A (HAV)
Beyond the preview
Go deeper on NCT00312858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00312858.